TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
23 hedge funds and large institutions have $7.57M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 25 → 23 (-2)
35% less capital invested
Capital invested by funds: $11.6M → $7.57M (-$4.04M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$50.5K |
| 2 |
Renaissance Technologies
New York
|
+$40.3K |
| 3 |
TI
Telemetry Investments
New York
|
+$15.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.6K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$72.5K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$41K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26K |
| 5 |
VF
Virtu Financial
New York
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| – | +$410 | +4 | New |
|
TCON Hedge Fund Activity: Q3 2019 in Review
23 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2019, worth a combined $7.57M — down 35% from $11.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TCON and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Wedbush Securities, adding an estimated $50.5K. The largest seller was 683 Capital Management, cutting an estimated $72.5K.
- 23 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2019, down from 25 in Q2 2019.
- Funds reported $7.57M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2019, down 35% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of -2 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Wedbush Securities, an estimated $50.5K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was 683 Capital Management, an estimated $72.5K sold.
Based on aggregated 13F filings for Q3 2019.